Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Mamot

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Reply to H.J.A. Adams and T.C. KweeChristoph Mamot
Swiss Medical Weekly|April 7, 2006
Targeting the epidermal growth factor receptor (EGFR)--a new therapeutic option in oncology?Christoph Mamot, Christoph Rochlitz
Praxis|January 4, 2018
Kathrin Vollmer, Christoph Mamot
International Journal of Molecular Sciences|February 28, 2013
Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practiceWolf-Dieter Janthur, Nathan Cantoni, Christoph Mamot
Neuroradiology|September 16, 2017
Diffusivity changes in bevacizumab-responding and -refractory meningiomaUlrich Roelcke, Jatta Berberat, Christoph Mamot, et al.
Sarcoma|July 15, 2016
Multimodality Treatment in Ewing's Sarcoma Family Tumors of the Maxilla and Maxillary Sinus: Review of the LiteratureDavid Thorn, Christoph Mamot, Fatime Krasniqi, et al.
International Journal of Pharmaceutics|February 22, 2015
Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trialAndreas Wicki, Reto Ritschard, Uli Loesch, et al.
Journal of Hematology & Oncology|March 18, 2017
Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohortDarius Juskevicius, David Jucker, Dirk Klingbiel, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|December 4, 2003
Liposome-based approaches to overcome anticancer drug resistanceChristoph Mamot, Daryl C Drummond, Keelung Hong, et al.
Journal of Hematology & Oncology|June 14, 2015
Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 studyAlexandar Tzankov, Nora Leu, Simone Muenst, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Reply to H.J.A. Adams and T.C. KweeChristoph Mamot
Swiss Medical Weekly|April 7, 2006
Targeting the epidermal growth factor receptor (EGFR)--a new therapeutic option in oncology?Christoph Mamot, Christoph Rochlitz
Praxis|January 4, 2018
Kathrin Vollmer, Christoph Mamot
International Journal of Molecular Sciences|February 28, 2013
Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practiceWolf-Dieter Janthur, Nathan Cantoni, Christoph Mamot
Neuroradiology|September 16, 2017
Diffusivity changes in bevacizumab-responding and -refractory meningiomaUlrich Roelcke, Jatta Berberat, Christoph Mamot, et al.
Sarcoma|July 15, 2016
Multimodality Treatment in Ewing's Sarcoma Family Tumors of the Maxilla and Maxillary Sinus: Review of the LiteratureDavid Thorn, Christoph Mamot, Fatime Krasniqi, et al.
International Journal of Pharmaceutics|February 22, 2015
Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trialAndreas Wicki, Reto Ritschard, Uli Loesch, et al.
Journal of Hematology & Oncology|March 18, 2017
Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohortDarius Juskevicius, David Jucker, Dirk Klingbiel, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|December 4, 2003
Liposome-based approaches to overcome anticancer drug resistanceChristoph Mamot, Daryl C Drummond, Keelung Hong, et al.
Journal of Hematology & Oncology|June 14, 2015
Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 studyAlexandar Tzankov, Nora Leu, Simone Muenst, et al.
Pageof 5